Phase I study of the anti-MET antibody onartuzumab in patients with solid tumors and MET-positive lung cancer

<i>MET</i> amplification occurs with or without <i>T790M</i> mutations in <i>EGFR</i> mutant lung tumors with acquired resistance to gefitinib or erlotinib

James Bean, Cameron Brennan, Jin‐Yuan Shih et al. · Proceedings of the National Academy of Sciences · 2007 · 1.6K citations

Medicine, Genetics, Oncology +17

Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Malignancies

Manuel Hidalgo, Lillian L. Siu, John Nemunaitis et al. · Journal of Clinical Oncology · 2001 · 1K citations

Medicine, Oncology, Pharmacology +15

Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer

David R. Spigel, Thomas J. Ervin, Rodryg Ramlau et al. · Journal of Clinical Oncology · 2013 · 477 citations · Full text

Medicine, Oncology, Pharmacology +17

Lung Cancer Cell Lines Harboring <i>MET</i> Gene Amplification Are Dependent on Met for Growth and Survival

Bart Lutterbach, Qinwen Zeng, Lenora J. Davis et al. · Cancer Research · 2007 · 320 citations

Medicine, Molecular Biology, Oncology +17

Levels of vascular endothelial growth factor, hepatocyte growth factor/scatter factor and basic fibroblast growth factor in human gliomas and their relation to angiogenesis

Nils Ole Schmidt, Manfred Westphal, Christian Hagel et al. · International Journal of Cancer · 1999 · 293 citations

Medicine, Cancer Biology, Oncology +17